Table 1.
Examples of FDA approved DDS in the market.
| Product name and category |
Year of approval |
Technology | Indication |
|---|---|---|---|
| Liposome & micelle | |||
| ➢ Doxil | 1995 | PEGylated liposomal doxorubicin | Various types of cancer |
| ➢ Daunoxome | 1996 | Liposomal daunorubicin | Advanced HIV-associated Kaposi's sarcoma |
| ➢ Ambisome | 1997 | Liposomal amphotericin B | Fungal infections |
| ➢ Depocyt | 1999 | Liposomal cytarabine | Lymphomatous meningitis |
| ➢ Visudyne | 2000 | Liposomal verteporfin | Age-related macular degeneration |
| ➢ Estrasorb | 2003 | Estradiol micellar nanoparticles | Moderate to severe vasomotor symptoms of menopause |
| ➢ DepoDur | 2004 | Liposomal morphine sulfate | Postoperative pain |
| Polymer-drug conjugate | |||
| ➢ Adagen | 1990 | PEGylated adenosine deaminase | Adenosine deaminase deficiency causing severe combined immunodeficiency disease |
| ➢ Oncaspar | 1994 | PEGylated L-asparaginase | Acute lymphoblastic leukemia |
| ➢ PEG-intron | 2001 | PEGylated interferon alfa-2b | Chronic hepatitis C |
| ➢ PEG-ASYS | 2002 | PEGylated interferon alfa-2a | Chronic hepatitis C & B |
| ➢ Neulasta | 2002 | PEGylated granulocyte colony-stimulating factor analog | Neutropenia |
| ➢ Somavert | 2003 | PEGylated recombinant analogue of the human growth hormone | Acromegaly |
| ➢ Macugen | 2004 | Pegylated anti-VEGF aptamer | Age-related macular degeneration |
| ➢ Mircera | 2007 | PEGylated erythropoetin receptor activators | Anaemia associated with chronic kidney disease |
| ➢ Cimzia | 2008 | PEGylated tumor necrosis factor alpha inhibitor | Crohn's disease |
| ➢ Krystexxa | 2010 | PEGylated urate oxidase | Gout |
| ➢ Omontys | 2012 | PEGylated peginesatide | Anemia caused by chronic kidney disease |
| Biodegradable materials | |||
| ➢ Zoladex | 1989 | PLGA/goserelin acetate | Prostate and breast cancer |
| ➢ Lupron Depot | 1989 | PLGA/leuprolide acetate | Prostate cancer and endometriosis |
| ➢ Gliadel | 1996 | Polifeprosan 20/carmustine | High-grade & recurrent glioblastoma multiforme |
| ➢ Sandostatin LAR | 1998 | PLGA-glucose/octreotide acetate | Acromegaly |
| ➢ Atridox | 1998 | PLA/doxycycline hyclate | Periodontal disease |
| ➢ Nutropin depot | 1999 | PLGA/recombinant human growth hormone | Growth hormone deficiency |
| ➢ Trelstar | 2000 | PLGA/triptorelin pamoatea | Advanced prostate cancer |
| ➢ Arestin | 2001 | PLGA/minocycline | Adult periodontitis |
| ➢ Eligard | 2002 | PLGA/leuprolide acetate | Advanced prostate cancer |
| ➢ Risperdal Consta | 2003 | PLGA/risperidone | Schizophrenia & bipolar I Disorder |
| ➢ Vivitrol | 2006 | PLGA/naltrexone | Alcohol dependence & opioid dependence |
| ➢ Somatuline | 2007 | PLGA/lanreotide | Acromegaly |
| ➢ Ozurdex | 2009 | PLGA/dexamethasone | Macular edema |
| Protein-based DDS | |||
| ➢ Zevalin | 2002 | Anti-CD20 monoclonal antibody/yttrium-90 | Non-Hodgkin's lymphoma |
| ➢ Bexxar | 2003 | Anti-CD20 monoclonal antibody/iodine-131. | non-Hodgkin's lymphoma |
| ➢ Abraxane | 2005 | Albumin/paclitaxel | Breast cancer |
| ➢ Brentuximab Vedotin | 2011 | Anti-CD30 monoclonal antibody/monomethyl auristatin E | Hodgkin lymphoma & systemic anaplastic large cell lymphoma |
Source: U S Food and Drug Administration website (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/). Websites of various pharmaceutical companies supplying the drugs.